IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#775
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$8.6B
Helen I. Torley
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = HALO ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HALO HALOZYME THERAPEUTICS, INC. | 59 | 76 | 79 | 52 | 14.0x | 14.5x | 1219.9% | 23.6% | 83.7% | 58.3% | 48.0% | 53.1% | 0.0% | 4389.0x | $8.6B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
HALOZYME THERAPEUTICS, INC. (HALO) receives a "Hold" rating with a composite score of 59.1/100. It ranks #775 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Headcount
390
HQ Base
SAN DIEGO, California
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for HALO.
View All RatingsROIC 18.4% vs WACC 7.8% (spread +10.6%)
GM 84% vs sector 44%, OM 58% vs sector 3%
Capital turnover 0.81x
Rev growth 53%, 10yr history
Interest coverage 109.2x, Net debt/EBITDA 3.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate HALOZYME THERAPEUTICS, INC. (HALO) as a Hold with a composite score of 59.1/100 at a current price of $70.71. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
HALOZYME THERAPEUTICS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 59.1/100 places it at rank #775 in our full universe.
Narrow
Medium
Standard
Undervalued
Gross margins of 84% signal strong pricing power.
Returns on equity of 1219.9% exceed cost of capital.
Value factor score of 79 suggests attractive pricing.
Leverage of 4389% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
HALOZYME THERAPEUTICS, INC. represents a hold based on multi-factor quantitative performance.
Our model assigns HALOZYME THERAPEUTICS, INC. a Hold rating, with a composite score of 59.1/100 and 3 out of 5 stars. Ranked #775 of 7,333 stocks, HALO presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
HALO earns a quality score of 76/100, indicating above-average business quality. The company reports a return on equity of 1219.9% (sector avg: -1.9%), gross margins of 83.7% (sector avg: 44.1%), net margins of 48.0% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
HALO carries a solid value score of 79/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 14.02x, an EV/EBITDA of 14.47x, a P/B ratio of 171.00x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
HALOZYME THERAPEUTICS, INC.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 53.1% vs. a sector average of 6.7% and a return on assets of 23.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
HALO demonstrates moderate momentum with a score of 52/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 53.1% year-over-year, while a beta of 0.54 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
HALO shows good financial stability with a score of 74/100. Key stability metrics include a beta of 0.54 and a debt-to-equity ratio of 4389.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
HALOZYME THERAPEUTICS, INC.'s short interest score of 29/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 4389.00x). At $8.6B (mid-cap), HALO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
HALOZYME THERAPEUTICS, INC. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #775 of 7,333 overall (89th percentile). Key comparisons include ROE of 1219.9% exceeding the -1.9% sector median and operating margins of 58.3% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HALO currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (79) vs Short Int. (29) — closing this gap could shift the rating.
EV/EBITDA 26% ABOVE SECTOR MEDIAN
ROE 64306% BELOW SECTOR MEDIAN
Gross Margin 90% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
Renaissance Group initiated a new $35.11 million position in Halozyme Therapeutics, acquiring 478,735 shares representing 1.32% of its U.S. equity assets. The biotech company offers innovative drug delivery technology and has demonstrated strong financial performance with consistent sales growth.
Halozyme Therapeutics (NasdaqGS:HALO) reported a quarterly net loss after recording a major impairment charge. The company outlined plans to actively pursue acquisitions to expand its drug delivery portfolio. These developments come alongside strong revenue growth in the latest quarter. Halozyme Therapeutics, trading at $70.98, is coming off a mixed stretch, with the share price down 10.6% over the past week but up 22.9% over the past year and 56.9% over five years. For investors, the...
In February 2026, Halozyme Therapeutics reported Q4 2025 revenue of US$451.77 million and full‑year revenue of US$1.40 billion, but a quarterly net loss of US$141.59 million driven by acquisition-related impairment and IPR&D charges, while reiterating 2026 revenue guidance of US$1.71 billion to US$1.81 billion. Alongside strong ENHANZE-driven revenue momentum and recent deals for new hyperconcentration drug delivery technologies, management signaled plans to keep using robust cash flow for...
Halozyme Therapeutics raised its 2026 and multi-year financial guidance, projecting total revenue growth of 23-30% year-over-year to $1.71-$1.81 billion. Royalty revenue is expected to exceed $1 billion in 2026, growing 30-35%, one year ahead of previous projections. The company acquired Surf Bio for $300 million and forecasts adjusted EBITDA of $1.125-$1.205 billion, with non-GAAP diluted EPS of $7.75-$8.25.
Meanwhile, Halo is planned to arrive on PlayStation later this year for the first time ever.